The US Supreme Court took part in a hearing on the billion-dollar legal dispute over the plant poison Glyphosate shown split. The judges looked at the manufacturer’s attempt Bavarianto avert thousands of lawsuits accusing the company of inadequate warnings about cancer risks.
The key question in the proceedings is whether federal regulations regarding warnings for weedkillers take precedence over state regulations. Bavarian argues that plaintiffs cannot accuse the company of violating national warning obligations because the US Environmental Protection Agency (EPA) does not
Cancer risk see and do not require a corresponding warning on the label.
However, a mixed picture emerged from the questions asked by the nine judges at the hearing. Judge Brett Kavanaugh commented that there may be a need for uniformity in such warnings. Chief Justice John Roberts, however, asked whether states should not be allowed to point out new risks. Roberts said states should have a way to respond to new warnings while federal authorities are still reviewing the issue.
Bayer is optimistic after hearing
The government of US President Donald Trump took part in the proceedings on the Bayer side. “If 50 different states just rush forward—Iowa says maybe cause that Cancer“California says it definitely causes cancer, another state says it doesn’t cause cancer at all, so put that on your label, then “that completely undermines the consistency of labeling,” said Justice Department attorney Sarah Harris.
Bayer reiterated its arguments in a statement about the hearing. Companies should not be able to be judged based on state law for complying with federal law. Anything else would result in a patchwork of warnings. »We welcome that the US Supreme Court “The issue of the uniformity of regulation and the primacy of federal law is carefully examined,” says the company’s statement.
Lawsuits against Bayer are not automatically ended even with a landmark ruling
Specifically, the judges are hearing Bayer’s appeal against a judgment from the state of Missouri in which a plaintiff was awarded $1.25 million. The man claims to have developed non-Hodgkin’s lymphoma after years of exposure to Roundup.
Roundup is in the
USA the brand name of the weed killer with the active ingredient glyphosate. Just recently Bayer concluded an expensive collective settlement in the dispute. The chemical company is also faced with claims from around 65,000 plaintiffs in federal and state courts in the USA.
A Supreme Court ruling in favor of Bayer could eliminate a central pillar of many lawsuits: the allegation that the company did not adequately warn of the risk of cancer under national law. However, this would not automatically end the wave of lawsuits. Many plaintiffs also allege negligence, misleading marketing or product defects. However, Bayer could also try to fend off these claims with reference to a favorable Supreme Court ruling.